The implementation of digital technologies for neuropsychiatric disorders such as Alzheimer’s disease (AD) is rapidly increasing. Advances in quantitative phenotypic assessment, through digital technology, can generate potentially significant improvements in patient-centered care (for example by allowing real life monitoring of treatment efficacy).

In this report, we provide an overview of digital technologies used to assess impairments occurring in AD at different stages of the disease, in particular those in the domains of cognitive abilities, social functioning, functional ability and independence, and sleep-wake patterns and night-time behaviours. Technologies reviewed include tests of cognition like executive function that can be performed on mobile devices, as well as passive functional measurements on systems such as wearables and remotely mounted sensors.